Marina Rajič, Ph.D.

Marina's extensive experience and expertise in pharmaceutical engineering position BioViros as a key player in viral vector CDMO services.

Her dedication to making a positive impact through biotech builds trust with clients and partners.

With a strong educational background, including a PhD in Biochemistry, Marina's knowledge and passion drive BioViros' strategic growth, ensuring investor confidence in the company's potential for success.

Saum Vahdat

Saum, CEO of Bridgewest Ventures, drives growth through strategic investments and incubation programs.

His focus on creative thinking in deep tech segments fosters innovation, benefiting social and economic progress.

With hands-on management, Saum accelerates commercialization, cultivates collaboration, and leverages his experience in finance and business development.

John Robson

John's extensive finance and investment experience benefit investors as a Director on BioViros' Board and General Manager of Bridgewest Ventures.

With 25 years of expertise in global equity, bonds, and treasury management, he maximizes returns. His involvement in the start-up community showcases innovation and identifying trends.

John's diverse expertise enables sound financial governance and strategic decision-making for investors.

Farzad Haerizadeh, Ph.D.

Farzad's 20+ years of experience in life sciences and biotech, focusing on cellular therapy and immuno-oncology, brings significant value to BioViros investors.

As Chief Scientific Officer at Bio4t2, he offers expertise in genomics, cell engineering, and therapeutics discovery.

His leadership in R&D roles and academic background further enhance his contributions to the company's innovation and success.

Thomas VanCott, Ph.D.

Tom brings extensive experience in virus and biologic product development.

As Chief Scientific Officer at a Boston-based biotech company and former Chief Technology and Strategy Officer at Catalent Cell & Gene Therapy, he enhances CMC services, leads product development, and drives strategic growth.

Tom's expertise positions him as a valuable asset to investors, ensuring BioViros stays innovative and meets market demands.

Stephen Chang, Ph.D.

Stephen, a human geneticist with 36 years of commercial experience, offers valuable expertise.

His specialization in stem cells, cell and gene therapy, and drug development, along with his leadership roles in startups and non-profits, ensures strategic guidance and successful execution.

Stephen's pioneering work in gene therapy and track record of drug successes further enhance his value to investors.

Rick Hancock

With over 35 years of experience in the life sciences industry, Rick's expertise in cGMP manufacturing, regulatory affairs, and operational excellence benefits BioViros.

His successful track record in driving growth at biotech companies and leadership roles make him a valuable asset for maximizing returns.